Variants on the promoter region of PTEN affect breast cancer progression and patient survival by Heikkinen, Tuomas et al.
RESEARCH ARTICLE Open Access
Variants on the promoter region of PTEN affect
breast cancer progression and patient survival
Tuomas Heikkinen
1, Dario Greco
1, Liisa M Pelttari
1, Johanna Tommiska
1, Pia Vahteristo
1, Päivi Heikkilä
2,
Carl Blomqvist
3, Kristiina Aittomäki
4 and Heli Nevanlinna
1*
Abstract
Introduction: The PTEN gene, a regulator of the phosphatidylinositol-3-kinase (PI3K)/Akt oncogenic pathway, is
mutated in various cancers and its expression has been associated with tumor progression in a dose-dependent
fashion. We investigated the effect of germline variation in the promoter region of the PTEN gene on clinical
characteristics and survival in breast cancer.
Methods: We screened the promoter region of the PTEN gene for germline variation in 330 familial breast cancer
cases and further determined the genotypes of three detected PTEN promoter polymorphisms -903GA, -975GC,
and -1026CA in a total of 2,412 breast cancer patients to evaluate the effects of the variants on tumor
characteristics and disease outcome. We compared the gene expression profiles in breast cancers of 10 variant
carriers and 10 matched non-carriers and performed further survival analyses based on the differentially expressed
genes.
Results: All three promoter variants associated with worse prognosis. The Cox’s regression hazard ratio for 10-year
breast cancer specific survival in multivariate analysis was 2.01 (95% CI 1.17 to 3.46) P = 0.0119, and for 5-year
breast cancer death or distant metastasis free survival 1.79 (95% CI 1.03 to 3.11) P = 0.0381 for the variant carriers,
indicating PTEN promoter variants as an independent prognostic factor. The breast tumors from the promoter
variant carriers exhibited a similar gene expression signature of 160 differentially expressed genes compared to
matched non-carrier tumors. The signature further stratified patients into two groups with different recurrence free
survival in independent breast cancer gene expression data sets.
Conclusions: Inherited variation in the PTEN promoter region affects the tumor progression and gene expression
profile in breast cancer. Further studies are warranted to establish PTEN promoter variants as clinical markers for
prognosis in breast cancer.
Introduction
Hereditary predisposition to breast cancer is caused by
variation in multiple genes affecting the cancer risk with
varying penetrance. Mutations in the main high pene-
trance genes BRCA1 and BRCA2 a r em o s t l yf o u n di n
families with multiple breast cancer cases particularly
with early onset and with ovarian cancer [1,2], and may
also affect breast cancer survival among the mutation
carriers [3,4]. Strong familial breast cancer predisposi-
tion is also present in rare cancer syndromes. Rare
germline mutations in the TP53 gene cause Li-Fraumeni
syndrome with highly increased risk for various malig-
nancies, including breast cancer [5]; whereas a common
TP53 variant in the population, R72P with functional
effect on p53 protein, has been shown to affect breast
cancer survival [6,7]. Another rare cancer syndrome
with increased breast cancer risk is Cowden syndrome
caused by germline mutations in the PTEN gene [8,9].
Patients with Cowden syndrome develop multiple
hamartomatous, mostly benign neoplasms especially on
the skin and mucous membrane, and also have a life-
time risk of 25 to 50% for breast cancer and an
increased risk of developing epithelial thyroid and endo-
metrial carcinomas [10]. PTEN mutations causing Cow-
den syndrome include a noticeable number of variants
on the promoter region affecting transcriptional levels
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tein [11,12]. The promoter of PTEN has been character-
ized in the 5’ region of the gene between nucleotides
-1344 and -747 from translation start site and it con-
tains binding sites, for example, for p53 and Sp1 tran-
scription factors [12-14]. So far, PTEN germline
variation increasing susceptibility to cancer outside
Cowden syndrome, or associating with tumor progres-
sion, has not been detected [15-17].
The PTEN (Phosphatase and tensin homolog) gene is a
tumor suppressor gene located on chromosome 10q23
and is mutated in multiple cancers [18,19]. The PTEN
protein, a dual specificity phosphatase with lipid and
protein phosphatase activities, functions as a negative
regulator of PI3K/Akt oncogenic pathway [20]. Altera-
tions in this pathway are among the most common
changes in human carcinogenesis [21]. In addition to
the PI3K/Akt pathway regulation, when localized to the
nucleus, PTEN takes part, for instance, in regulation of
chromosomal integrity, acetylation of p53, DNA-damage
response and the induction of apoptosis [22]. In breast
tumors, PTEN expression is often lost through muta-
tions or epigenetic mechanisms [23,24]. Reduced PTEN
expression [24-26] and the dysregulated PI3K/Akt path-
way [27,28] have been associated with aggressive breast
cancer phenotype and poor outcome of the disease.
Breast tumors originating by dysfunctional BRCA1 often
suffer PTEN loss through gross mutations [29]. Further-
more, tumors with reduced PTEN protein expression
have been shown to carry a particular gene expression
signature that predicts worse outcome and metastasis in
breast cancer as well as in prostate and bladder carcino-
mas [30]. Recently, a moderate decrease in PTEN
expression to 80% of the normal level has been shown
to increase susceptibility to develop cancer in mice, par-
ticularly in mammary tissue [31].
To investigate the role of potentially regulatory PTEN
germline genetic variation on clinical characteristics and
survival in breast cancer, we screened the promoter
region of PTEN from 330 familial breast cancer cases.
We genotyped the detected promoter variants in a large
set of familial and unselected breast cancer patients to
evaluate the effects of the variants on tumor phenotype
and disease outcome. We also compared the gene
expression profiles in breast cancer tumors of the var-
iant carriers and non-carriers, with further survival ana-
lyses on the differentially expressed genes in breast
cancer gene expression data sets.
Materials and methods
Subjects
The promoter region of the PTEN gene was screened
for germline variation in 330 patients from families with
multiple cases of breast or ovarian cancer, found
negative for BRCA1 and BRCA2 mutations by screening
the coding regions of the genes using denaturing gradi-
ent gel electrophoresis (DGGE) and for the large exon
11 of BRCA1 and exons 10 and 11 of BRCA2 using pro-
tein truncation test (PTT).
Altogether 1,870 unselected breast cancer patients and
542 additional familial cases were included in the geno-
typing of the promoter variants. The unselected cohort
consisted of two series of patients, collected in Helsinki
University Central Hospital’s Department of Oncology
in 1997 to 1998 and 2000 (884 patients) [32,33], and on
the Department of Surgery in 2001 to 2004 (986
patients) [34] covering 79% and 87% of all consecutive
newly diagnosed breast cancer patients, respectively.
The familial breast cancer cases were collected at Hel-
sinki University Central Hospital’s Department of Clini-
cal Genetics. The familial series consisted of patients
with strong familial background with three or more
breast or ovarian cancers among first or second degree
relatives, including the proband, and of familial cases
with one first degree relative and the proband affected
with breast cancer. The BRCA1 and BRCA2 mutations
were excluded as described earlier [35].
The cancer diagnoses were confirmed through the
Finnish Cancer Registry and hospital records. Informa-
tion on death due to breast cancer was obtained from
the Finnish Cancer Registry, which collects diagnostic as
well as death information on all cancer patients in Fin-
land, and the distant metastasis data were retrieved
from hospital records collected with routine follow-up
investigations of breast cancer patients for five years
from diagnosis. The survival was calculated as the time
from the diagnosis of the first invasive breast cancer to
the date of death due to breast cancer or of diagnosis of
a distant metastasis. This study was performed with
informed consent from the patients as well as permis-
sion from the Ethics Committee of the Helsinki Univer-
sity Central Hospital and from the Ministry of Social
Affairs and Health in Finland.
Information on tumor histology, grade, size, nodal sta-
tus and distant metastases at diagnosis were collected
from pathology reports [36]. Additionally, a breast can-
cer pathologist re-reviewed 1,423 tumors (56% of all) for
tumor histology and grade, according to Scarff-Bloom-
Richardson modified by Elston and Ellis [37]. Estrogen
receptor (ER) and progesterone receptor (PR) status
were retrieved from pathology reports [36]. For both ER
and PR status, samples with > 10% of the cancer cells
stained positive with immunohistochemistry were con-
sidered as positive. HER2 status was based on immuno-
histochemical staining (samples with < 10% of the cells
stained were considered negative and > 90% positive)
and gene amplification with chromogenic in situ hybri-
dization (CISH; over six replications was considered
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negative) on tumor microarrays as described in [38].
p53 protein expression was evaluated by immunohisto-
chemical staining as previously described [6]. Samples
were defined as positive for p53 when more than 20% of
the cancer cells were positive for the staining. Ki67 sta-
tus was defined as described [39] with strong positive
(3) expression considered when ≥ 30%, intermediate (2)
when 20 to 29%, weak positive (1) when 5 to 19%, and
negative (0) when < 5% of the cancer cells were stained
with Ki67 antibody. Altogether 2,401 invasive breast
tumors from 2,256 patients were taken into the analysis
of the variants’ association with tumor characteristics.
A total of 2,204 patients with invasive breast cancer
and follow-up data available were included in the survi-
val analysis. The median follow-up time in 10-year
breast cancer specific analysis was 83 months, and for
5-year breast cancer death or distant metastasis free sur-
vival (BDDM) was 47 months. Of all patients in the sur-
vival analysis, 298 died from breast cancer within 10
years from diagnosis, and 352 developed distant metas-
tasis or died of breast cancer within 5 years from
diagnosis.
Mutation screening and genotyping
The complete promoter region between nucleotides
-1344 and -747 [12] of the PTEN gene were screened for
v a r i a t i o no ng e n o m i cD N Ai s o lated from blood samples
of 330 familial breast cancer patients using conformation
sensitive gel electrophoresis (CSGE) heteroduplex analy-
sis. All variants were verified by bidirectional sequencing.
CSGE was further used to determine the genotypes of
the variants -903GA and -975GC, which were located in
the same CSGE amplicon (covering nucleotides from
-617 to -1087) in the complete data set. All samples
showing different banding patterns on gel were verified
by sequencing. The -1026CA variant was genotyped
using Sequenom i-PLEX with service provided by the
Finnish Genome Center. Of the 2,412 patients geno-
typed, a successful result was obtained from 2,375
(98.5%) individuals for -1026CA and from 2,369 (98.2%)
individuals for -903GA and -975GC variants.
Gene expression analysis
Total RNA was extracted from primary breast tumors of
183 patients, including 10 cases carrying a promoter
variant. Of them, 151 were collected as a part of the
unselected series and 32 patients belonged to additional
familial breast cancer cases. The samples were processed
and hybridized to Illumina HumanHT-12 v3 Expression
BeadChips (Illumina Inc, San Diego, CA, USA) contain-
ing 24,660 Entrez Gene entities, according to the manu-
facturer’s recommendations (http://www.illumina.com).
Microarray raw data were imported into R v2.11
(http://cran.r-project.org) and processed by the methods
included in the BioConductor facilities [40]. Briefly, after
quality control [41], the data were normalized using the
quantile method [42] and the gene expression matrix
from the tumors of 10 PTEN promoter variant carriers
and 10 wild type controls matched with tumor histology,
estrogen and progesterone receptor status, HER2 over-
expression/amplification, grade, tumor size, p53 status
and Ki67 expression was obtained by averaging the
probes mapping to the same Entrez Gene IDs (http://
www.ncbi.nlm.nih.gov/Entrez). Differential expression
between the tumors of promoter variant carriers and
non-carriers was assayed by moderated t-test. Genes
with P < 0.01 were considered to be significant [43] and
further analyzed. Functional annotation was performed
on the differentially expressed gene list using the
DAVID functional annotation tools (http://david.abcc.
ncifcrf.gov/) [44]. The categories with Fisher’se x a c tt e s t
P-value < 0.05 were considered to be significantly
enriched.
The 160 differentially expressed genes were further
used to cluster the patients of the whole data set and
three publicly available breast cancer gene expression
series into two groups by an unsupervised clustering
method. The K-means algorithm was iterated 100,000
times to ensure maximum reliability and the results
were stabilized by imposing a pre-defined random num-
ber selection algorithm at the beginning of the process.
Statistical analyses
Statistical analyses were performed using SPSS 15.0 soft-
ware (SPSS, Inc., Chicago, IL, USA). Pearson’s c
2 test
was used to evaluate the association of different geno-
types on tumor characteristics. Fischer’s exact test was
applied when the expected number of cell count was
less than five. All P-values were two-sided. The effects
of the variants on the prognosis of the patients were
analyzed using Kaplan-Maier survival plots with Log-
Rank test. The survival analyses were performed on
long-term breast cancer specific 10-year follow-up and
on short term combined analysis on breast cancer death
or distant metastasis (BDDM) with 5-year follow-up.
The survival hazard ratios were calculated using univari-
ate Cox’s regression analysis. Independence of the var-
iants in relation to common prognostic factors (tumor
size, nodal status, primary metastasis, estrogen receptor,
progesterone receptor, Her2, p53, Ki67, grade) was eval-
uated by constructing Cox’s multivariate models with
SPSS 15.0 backward conditional algorithm. All variables
were set as categorical. For increased statistical power,
the three promoter variants were combined for the mul-
tivariate analysis.
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Variant discovery
Two previously known polymorphic variants (-1026CA/
rs34149102 and -903GA/rs1044322) and one novel var-
iant (-975GC) were observed in the screening of the 330
familial breast cancer patients. The promoter variant
numbering as nucleotides from translation start site is
matched with the numbering used by Zhou et al. [12].
In the complete data set of 1,870 unselected and 542
additional familial breast cancer cases the -1026CA gen-
otype was present in 2%, -975GC in 1%, and -903GA in
3% of the patients. Two patients were also found with
both -1026CA and -903GA, and one patient with
-903GA and -975GC variants.
PTEN promoter variants associate with markers of
aggressive disease and survival of breast cancer patients
To evaluate the possible associations of the three recur-
rent PTEN promoter variants detected in the patient
samples (-903GA, -975GC, and -1026CA) with the
tumor phenotype, we calculated the correlations
between the PTEN promoter variant status and tumor
characteristics (tumor size, lymph node and distant
metastasis at diagnosis, tumor histology, grade, estrogen
and progesterone receptor status, HER2 over-expression,
p53 status, and Ki67 proliferation marker expression)
(Additional file 1). The -975GC variant was found to
associate with a significantly higher frequency with dis-
tant metastasis at diagnosis (OR 4.99, 95% CI 1.69 to
14.78; P (Fischer) = 0.013) and the -1026CA variant
with high expression of Ki67 (OR 2.21; 95% CI 1.15 to
4.28; P = 0.015).
The effects of the variants on disease outcome were
evaluated for 10-year breast cancer specific survival and
5-year BDDM free survival by Kaplan-Meier estimates
with LogRank test and Cox’s regression analyses. All
three promoter variants were found to be significantly
associated with worse long term survival and variants
-903GA and -975GC also with short term breast cancer
death or distant metastasis free survival (Figure 1).
Patients with -903GA, -975GC or -1026CA variant had
10-year breast cancer specific survival rates of 71% (P =
AB
Figure 1 Kaplan-Meier plots of cumulative survival for breast cancer patients carrying a PTEN promoter variant. The plots for patients
with different variants are shown for -903GA in green, -975GC in orange, -1026CA in red, and for non-carrier Wild type in blue. All variants
showed significant long term survival effect in breast cancer specific 10-year analyses (A) with cumulative survival at 120 months of 82.7% (95%
CI 80.7 to 84.7%) for non-carriers, 71.3% (95% CI 58.8 to 83.8%) for -903GA (P = 0.016), 57.2% (95% CI 33.1 to 81.3%) for -975GC (P = 0.002), and
65.3% (95% CI 47.1 to 83.5%) for -1026CA (P = 0.014). Two variants also showed significant effect in five year breast cancer death or distant
metastasis free analysis (B) with cumulative survival at 60 months of 82.5% (95% CI 80.7 to 84.3%) for non-carriers, 64.3% (95% CI 51.2 to 77.3%)
for -903GA (P = 0.002), 63.8% (95% CI 44.4 to 83.2%) for -975GC (P = 0.010), and 76.9% (95% CI 62.6 to 91.0%) for -1026CA (P = 0.279).
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tively, compared to survival rate of 83% of non- carriers
(Figure 1A). In the five-year analysis, the cumulative
survival for breast cancer specific death or distant
metastasis was 64% for -903GA carriers (P = 0.002),
64% for -975GC carriers (P = 0.010), and 77% for
-1026CA carriers (P = 0.279) compared to 83% for the
non-carriers, with the difference for the first two var-
iants being statistically significant (Figure 1B). The uni-
variate Cox’s regression analyses concurred with the
results of the Kaplan-Meier analysis (Table 1), showing
that harboring any of the three variants affected the 10-
year breast cancer specific survival with a hazard ratio
of 2.17 (P = 0.00002) and the 5-year BDDM with a
hazard ratio of 1.97 (P = 0.00011). The multivariate
Cox’s regression models adjusted with conventional
prognostic markers demonstrate that carrying any of the
three promoter variants is an independent prognostic
factor, with approximately two-fold increased risk of
death or distant metastasis for the carriers (Table 2).
Patients with PTEN promoter variants develop breast
tumors with differential gene expression signature
We used microarray expression analysis to compare
gene expression patterns in breast tumors from 10
patients with -903GA, -975GC, or -1026CA PTEN pro-
moter variant and 10 matched non-carriers. A total of
160 genes were found to be differentially expressed
(Additional file 2) with P < 0.01. No genes were signifi-
cant after post hoc correction, hence we used a nominal
P-value of 0.01 as the threshold of significance. Of the
160 genes, 104 genes were over-expressed and 56
under-expressed in the tumors of variant carriers. The
differential expression between the subjects of two
groups spanned between 1.81 and -1.85 base 2 log fold
changes (3.5/-3.6 in natural scale). The samples success-
fully clustered using the expression profiles of the 160
differentially expressed genes as visualized in Figure 2,
suggesting that this gene-set can be considered a signa-
ture for PTEN promoter variant carriers. The gene
expression profiles of the tumors of different variant
carriers co-segregated withi nt h es a m eb r a n c h e so ft h e
hierarchical cluster. There was no segregation when the
whole expression matrix (24,660 genes) was used in
hierarchical clustering analysis. Differences in the
expression levels of the PTEN gene could not be
detected in microarray analysis between promoter var-
iant carriers and non-carriers, possibly due to the limita-
tions of the technology to detected small differences.
The differentially expressed genes were further anno-
tated for their biological themes using DAVID func-
tional annotation tools (http://david.abcc.ncifcrf.gov/)
[44]. The genes up-regulated in the tumors of PTEN
promoter variant carriers represented several biological
families related to ATP-binding, protein phosphorylation
and protein kinases. Likewise, functional groups of
DNA-binding and transcription factor proteins were
over-represented among the down-regulated genes
(Additional file 3).
We compared the 160 differentially expressed genes
with the gene expression signature of PTEN deficient
tumors defined previously by Saal et al. [30]. The enti-
ties in the Saal signature list could be mapped to 151
unique Entrez Gene IDs. Of these, only one (TUBB2C,
EG. 10383) was also found among the differentially
expressed genes reported here. On the functional level,
however, the Saal genes represented, among others, bio-
logical themes overlapping with those found here, such
as phosphoprotein and ATP-binding from the up-regu-
lated genes as well as the DNA-binding and transcrip-
tion regulation from the down-regulated gene list.
The gene signature of the PTEN promoter variant carrier
tumors stratifies patients into two groups with different
recurrence free survival
We investigated the effects of the 160 signature genes
on breast cancer survival and recurrence in a larger data
set of 183 breast tumors (Helsinki data set) and in three
independent publicly available breast cancer gene
expression data sets with survival information from Swe-
den (GSE1456 [45] and GSE4922 [46]) and from the
Netherlands (GSE2034 [47]). For all the data sets ana-
lyzed, the expression patterns for the signature genes
were retrieved from the larger expression matrix and
unsupervised segregative clustering (k-means) was used
to assign the samples to two groups, which were then
compared by log-rank test. The survival curves were
visualized in Kaplan-Meier plots. The two groups of
patients defined according to the expression of the 160
genes had distinct BDDM survival in the Helsinki data
s e t( F i g u r e3 A )( P =2 . 6 9 9×1 0
-6). The survival effect
was further confirmed in two independent data sets
(Figure 3B, C), and while the trend of the effect could
be seen also in the third data set, the difference did not
reach a statistically significant level (Figure 3D). We
further applied the same approach to see if the gene
Table 1 Univariate Cox regression survival analysis of
breast cancer patients with PTEN promoter variants.
10-year breast cancer specific 5-year BDDM
Variant P-value HR 95% CI P-value HR 95% CI
-903GA 0.01521 1.90 1.13 to 3.20 0.00201 2.07 1.31 to 3.29
-975GC 0.00357 2.68 1.38 to 5.21 0.01220 2.33 1.20 to 4.52
-1026CA 0.01829 2.06 1.13 to 3.77 0.28165 1.44 0.74 to 2.79
any 0.00002 2.17 1.52 to 3.10 0.00011 1.97 1.40 to 2.79
The 10-year breast cancer-specific survival and the 5-year breast cancer death
or distant metastasis (BDDM) free survival analyses show significant
association with reduced survival for all three PTEN promoter variants.
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defined by Saal et al. [30] would have similar survival
effects. The Saal signature also divided patients into two
survival groups in all data sets with LogRank P-values in
the Helsinki set P =1 . 0 6×1 0
-6,i nt h eS t o c k h o l ms e tP
= 0.003, in the Rotterdam set P = 0.001, and in the
Uppsala set P = 0.002. In these data sets, 93%, 74%, 69%
and 76% of the tumors, respectively, clustered in corre-
sponding survival groups as those in the analysis by our
PTEN promoter variant signature.
Discussion
Here we have investigated germline genetic variation in
the promoter region of the PTEN gene for breast cancer
patient survival, with further gene expression analysis of
breast tumors from the variant carriers. The -903GA,
-975GC and -1026CA promoter variants were found to
predict poor survival of breast cancer patients. In multi-
variate analysis adjusted for conventional prognostic fac-
tors, carrying any of the three promoter variants was an
independent predictor of poor prognosis and approxi-
mately doubled the risk of the patients for distant
metastasis or death within the follow-up time. One of
the variants, -975GC, was also found to associate with
having distant metastasis already at the time of diagno-
sis, and the -1026CA was found to be associated with
increased proliferation of the tumor cells. These results
s u g g e s tt h a tt h ePTEN promoter variation has an effect
on increased metastatic potential and progression of the
tumor.
All the variants detected lie on the promoter region
on nucleotides evolutionarily conserved in higher mam-
mals (Additional file 4) and may affect the PTEN
expression, although other functional mechanisms of the
variants cannot be excluded at this phase. The PTEN
gene expression levels in the variant carrier tumors were
comparable to those in the non-carriers, possibly due to
the limitations of the technology to detect small differ-
ences. This is consistent with the recent findings show-
ing that even a subtle decrease in PTEN dose increased
cancer susceptibility in mice, affected the cellular prolif-
eration particularly in mouse mammary tissue, and
altered the expression of proliferation related genes [31].
Indeed, the -1026CA variant associated significantly
with proliferation rate of the tumors. Moreover, consid-
ering the role of PTEN as a dosage dependent tumor
suppressor [48], even subtle changes in the expression
of the PTEN gene might play a role in the very early
stages of tumorigenesis. However, further studies will be
needed to determine the functional effects of the
variants.
The gene expression analysis showed 160 genes being
differentially expressed in the tumors of the variant car-
riers compared to non-carrier tumors, with similar and
indistinguishable patterns in the tumors of the patients
with -903GA, -975GC or -1026CA variant. The up-regu-
lated genes annotated in large proportion to entities
related to ATP or nucleoside binding and phosphoryla-
tion while DNA binding and transcriptional functions
were common among down-regulated genes (Supple-
mentary Table S4). The most strongly down-regulated
gene in the signature was interestingly BAMBI (BMP
and Activin Membrane-Bound Inhibitor) (Supplemen-
tary Table S3). High expression of BAMBI has been
shown to predict metastatic potential in colorectal can-
cer [49] and it is epigenetically silenced in high grade
bladder carcinomas [50]. However, the signature repre-
sents a complex network of downstream effects of the
Table 2 Multivariate Cox regression survival analysis of the PTEN promoter variants, adjusted for common prognostic
factors.
10-year breast cancer specific 5-year BDDM
Category P-value HR 95% CI Category P-value HR 95% CI
Tumor size 1.67 × 10
-6 Tumor size 9.89 × 10
-13
2 vs 1 0.0006 1.92 1.32 to 2.79 2 vs 1 1.73 × 10
-6 2.4 1.68 to 3.44
3 vs 1 4.12 × 10
-6 4.27 2.30 to 7.92 3 vs 1 2.38 × 10
-8 5.21 2.92 to 9.30
4 vs 1 0.0001 3.80 1.95 to 7.41 4 vs 1 3.49 × 10
-11 6.63 3.79 to 11.61
Nodal metastasis 1.70 × 10
-10 3.57 2.41 to 5.27 Nodal metastasis 4.03 × 10
-10 3.08 2.17 to 4.39
Distant metastasis 4.63 × 10
-10 5.51 3.22 to 9.42
progesterone receptor 0.0025 1.69 1.20 to 2.38 progesterone receptor 0.0398 1.39 1.02 to 1.91
Grade 2.12 × 10
-5 Grade 0.0001
2 vs 1 0.3528 1.31 0.74 to 2.31 2 vs 1 0.0111 2.07 1.18 to 3.63
3 vs 1 0.0004 2.76 1.57 to 4.86 3 vs 1 4.78 × 10
-5 3.25 1.84 to 5.74
PTEN promoter variant 0.0119 2.01 1.17 to 3.46 PTEN promoter variant 0.0381 1.79 1.03 to 3.11
Models were built for 10-year breast cancer specific survival (left) and for 5-year breast cancer death or distant metastasis free survival (right). Factors included in
the analysis were tumor size, nodal status, primary metastasis (for 10-year breast cancer specific only), estrogen receptor, progesterone receptor, Her2, p53, Ki67,
and grade. Only the variables significant in the final step of the model are presented in the tables, demonstrating that carrying any of the PTEN promoter
variants is an independent prognostic factor.
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overall effect on tumor phenotype and patient survival.
In the comparison of the differentially expressed genes
found in this study and the somatic PTEN expression sig-
nature (by PTEN protein loss) in the study by Saal et al.
[30] little overlap was seen at the single gene level. This
was not surprising considering the profound differences in
the microarray technologies used in the two studies, such
as probe lengths and densities, as well as the laboratory
procedures and analysis protocols, which together can
make the comparison of the expression levels of individual
genes in different studies challenging [51]. Furthermore,
the changes in the expression of the PTEN gene caused by
the inherited germ line variation could predispose the car-
riers already in early tumorigenesis to specific tumor pro-
gression pathways, whereas the Saal signature represents
effects of somatic loss of PTEN expression at some later
stage of tumor progression. However, the Saal gene list
and the signature described here were overall functionally
overlapping, representing similar gene functions.
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Figure 2 The tumor gene expression signatures of the 160 differentially expressed genes. The expression of the signature genes in the
tumors of PTEN promoter variant carriers and non carriers show differential clustering separating the two groups.
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Helsinki expression data set of 183 breast tumors
revealed a correlation with the disease recurrence. This
effect was also confirmed in independent, publicly avail-
able breast cancer gene expression data sets. The goal of
this analysis was to evaluate the potential of the signa-
ture genes in identifying groups of patients with differ-
ent survival rates. In this analysis, some of the signature
genes can be either up- or down-regulated in different
patients. Hence, rather than evaluating the differential
expression as such, the overall combinatorial effect of
the signature genes needs to be evaluated. To achieve
this, we applied the approach successfully used by Lukes
et al. [52], in which the patients are divided into two
groups by clustering analysis based on the overall
expression of the signature genes. The survival
differences between the two groups were then evaluated.
Our results show that the expression signature of 160
genes associates with breast cancer prognosis in inde-
pendent breast tumor gene expression data sets. These
results emphasize the biological importance of the sig-
nature genes and their impact on breast cancer progres-
sion and show that the signature has a similar effect on
breast cancer recurrence as the promoter variants.
Indeed, the metastasis susceptibility effect by the germ-
line variants is likely mediated by their downstream
effects on the signature genes. Furthermore, when the
gene signature of somatically aberrant PTEN expression
by Saal et al. was used for the survival analysis, we
found the clustering of the tumors into corresponding
survival groups in each data set was highly correlated
between the two signatures. This highlights the
A B
C D
Figure 3 Survival differences by the expression of the signature genes in independent breast cancer data sets. Expression patterns of
the 160 signature genes affect the five-year breast cancer recurrence in Helsinki breast cancer data set GSE24450 (A) as well as in other publicly
available breast cancer gene expression data sets from Stockholm GSE1456 (B) and from Rotterdam GSE2034 (C). Similar trend, although not
significant was present also in Uppsala GSE4922 data set (D).
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Page 8 of 11biological similarity of the two signatures and overall
supports the inherited promoter variant’s effect on the
PTEN mediated tumor suppression.
Conclusions
The PTEN gene and the AKT/PI3K pathway are among
the most intensively studied targets in cancer research.
So far, no associations of germline genetic variation in
PTEN have been shown to exist with clinically relevant
features outside hamartomatous polyposis syndromes.
The genetic analyses together with gene expression ana-
lysis in this study suggest that inherited genetic variation
in the PTEN promoter region affect the metastatic
potential and tumor progression as well as gene expres-
sion profile in breast cancer, also with clinical implica-
tions for reduced survival of breast cancer patients.
These findings also further strengthen the proposed role
of germline variation on gene expression signatures and
on metastatic potential of the tumors [52]. Further stu-
dies are warranted to establish the PTEN promoter var-
iants as clinical markers for prognosis in breast cancer.
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